Results 111 to 120 of about 5,781 (240)

Enhancing Diagnostic Accuracy in Sinonasal Neuroendocrine Tumors: The Case for DOTATATE PET Over FDG PET

International Forum of Allergy &Rhinology, Volume 15, Issue 10, Page 1023-1027, October 2025.
ABSTRACT Neuroendocrine tumors (NET) are a heterogeneous group of neoplasms that arise from neuroendocrine cells and commonly originate in the GI tract, lungs, and pancreas, but can also present in the skull base and paranasal sinuses. While fluorodeoxyglucose positron emission tomography (FDG PET) scans are routinely used in the evaluation of ...
Michael Sabbaj, Anandraj Kanwar, Jessica W. Grayson, Nyall R. London, Shirley Y. Su, Carl H. Snyderman, Brian D. Thorp, Dennis Tang, David Gudis, Eric W. Wang, Edward C. Kuan, Garett W. Choby, Mathew Geltzeiler   +12 more
wiley   +1 more source

Advanced Peptide Receptor Radionuclide Therapy to Overcome Refractory Hypoglycemic Insulinoma: A Case Report and Review of the Literature

Journal of Medical Sciences
We reported the case of a 42-year-old man with refractory hypoglycemia caused by an inoperable malignant insulinoma and multiple liver metastases. The patient initially received bi-weekly intramuscular injections of octreotide long-acting release and a ...
Yi-Hsiang Huang, Sheng-Chiang Su, Tzu-Chuan Huang   +2 more
doaj   +1 more source

Safety of selective internal radiation therapy (SIRT) with yttrium-90 microspheres combined with systemic anticancer agents: expert consensus [PDF]

, 2017
Selective internal radiation therapy (SIRT) with microspheres labelled with the β-emitter yttrium-90 (Y-90) enables targeted delivery of radiation to hepatic tumors. SIRT is primarily used to treat inoperable primary or metastatic liver tumors.
Brown, DB, Fakih, M, Feilchenfeldt, J, Gibbs, P, Kennedy, A, Knuth, A, Marshall, J, Pittari, G, Sangro, B, Sharma, RA, Soulen, MC, Wasan, H   +11 more
core   +1 more source

Glucagonoma and Glucagonoma Syndrome: An Updated Review

Clinical Endocrinology, Volume 103, Issue 4, Page 417-426, October 2025.
ABSTRACT Background Glucagonoma is a rare well‐differentiated slowly proliferating pancreatic neuroendocrine tumour, characterized by several manifestations including necrolytic migratory erythema, weight loss, diabetes and anaemia. Aim The purpose of the current review was to acknowledge literature about this rare tumour discerning the clinical ...
Sofia Anelli, Rossella Mazzilli, Virginia Zamponi, Beatrice Giorgini, Bianca Golisano, Camilla Mancini, Flaminia Russo, Francesco Panzuto, Antongiulio Faggiano   +8 more
wiley   +1 more source

Treatment Patterns of Pancreatic Neuroendocrine Tumor (pNET) Patients at Two Canadian Cancer Centres

Current Oncology
Pancreatic neuroendocrine tumors (pNETs) are rare but increasingly prevalent malignancies with varied prognoses and a diverse range of treatment options, including surgery, somatostatin analogues (SSAs), chemotherapy, targeted therapy, and peptide ...
Gautham Nair, Morgan Black, Kathie Baer, Stephen Welch, David T. Laidley, Rachel Goodwin, Macyn Leung, William J. Phillips, Michael Vickers, Tim Asmis, Horia Marginean, Elena Tsvetkova   +11 more
doaj   +1 more source

Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives [PDF]

, 2017
urpose Everolimus has been shown to be effective for advanced pancreatic neuroendocrine tumours (pNETs), but its positioning in the therapeutic algorithm for pNETs is matter of debate.
Badalamenti, G., Colao, A., Faggiano, A., Fanciulli, G., Gallo, M., Giordano, C., Malandrino, P., Rota, F.   +7 more
core   +1 more source

Pathological complete response of initially unresectable multiple liver metastases achieved using combined peptide receptor radionuclide therapy and somatostatin analogs following pancreatic neuroendocrine tumor resection: a case report

Surgical Case Reports
Background Peptide receptor radionuclide therapy (PRRT) serves as a novel and effective treatment option for somatostatin receptor-positive unresectable liver metastases of pancreatic neuroendocrine tumors (PNETs).
Ryosuke Umino, Satoshi Nara, Noritoshi Kobayashi, Takahiro Mizui, Takeshi Takamoto, Daisuke Ban, Minoru Esaki, Nobuyoshi Hiraoka, Kazuaki Shimada   +8 more
doaj   +1 more source

Peptide receptor radionuclide therapy in the management of neuroendocrine tumors (Neoplasms)*: Fundamentals and salient clinical practice points for medical oncologists

Indian Journal of Medical and Paediatric Oncology, 2019
This editorial commentary is an expert summary of “Peptide Receptor Radionuclide Therapy (PRRT),” encompassing the essential fundamentals and salient clinical practice points, deliberated and designed in a point-wise manner with theme-based subheadings ...
Sandip Basu, Rahul Parghane, Rohit Ranade, Pradeep Thapa, Anant Ramaswamy, Vikas Ostwal, Bhawna Sirohi, Dipanjan Panda, Shailesh V Shrikhande   +8 more
doaj   +1 more source

Somatostatin receptor PET/CT in restaging of typical and atypical lung carcinoids [PDF]

, 2015
Background To assess the role of somatostatin receptor (SR) PET/CT using Ga-68 DOTATOC or DOTATATE in staging and restaging of typical (TC) and atypical (AC) lung carcinoids.
Apostolopoulou, Konstantina, Arsenic, Ruza, Brenner, Winfried, Denecke, Timm, Pascher, Andreas, Pavel, Marianne, Prasad, Vikas, Steffen, Ingo G., Tischer, Elisabeth   +8 more
core   +2 more sources

Towards Effective Targeted Alpha Therapy for Neuroendocrine Tumours: A Review

Pharmaceuticals
This review article explores the evolving landscape of Molecular Radiotherapy (MRT), emphasizing Peptide Receptor Radionuclide Therapy (PRRT) for neuroendocrine tumours (NETs).
Paul M. D. Gape, Michael K. Schultz, Graeme J. Stasiuk, Samantha Y. A. Terry   +3 more
doaj   +1 more source